Geistlich unveils vallos – a new demineralized allograft that sets the pace for regeneration

08 Nov 2022
www.nsmedicaldevices.com
This Geistlich Select product line brings an added confidence to regenerative procedures Introducing vallos from Geistlich North America. (Credit: PR Newswire/ Geistlich Pharma North America, Inc.) Geistlich Pharma North America Inc. is setting the pace for expanded treatment options with the introduction of vallos, our first demineralized allograft. With two formulations for treatment flexibility, vallos granules are ideally suited for smaller routine defects while vallos f fibers are designed for larger more complex defects. This Geistlich Select product line brings an added confidence to regenerative procedures, with: Verified osteoinductive potential in every lot Consistent product quality Proven regenerative capacity by exhibiting all five elements of bone formation1 Vital bone after 18-20 weeks Geistlich Select: Geistlich is proud of the quality and safety of its products and consistently employs rigorous scientific validation and strict manufacturing processes. Extensive research and collaboration have created a partnership to bring you select allograft materials designed for clinical versatility and success. Demineralized vallos and vallos f offer clinicians more options to enhance their ability to manage a variety of clinical indications and are the first products to become part of the Geistlich Select family. “We are excited to bring these first allograft innovations to clinicians, which provides them with new options for their regenerative procedures. We will be expanding our allograft product line with additional solutions in the near future, as part of our Geistlich Select family,” said Les Burrows, General Manager of Geistlich Pharma North America. Source: Company Press Release
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.